Cue Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . Cue Biopharma
CUE Stock  USD 1.31  0.06  4.80%   
Cue Biopharma financial statements provide useful quarterly and yearly information to potential Cue Biopharma investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Cue Biopharma financial statements helps investors assess Cue Biopharma's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Cue Biopharma's valuation are summarized below:
Gross Profit
-27.8 M
Market Capitalization
79.2 M
Enterprise Value Revenue
6.0372
Revenue
9.5 M
Earnings Share
(0.91)
There are over one hundred nineteen available fundamental signals for Cue Biopharma, which can be analyzed over time and compared to other ratios. Investors should ensure to validate all of Cue Biopharma's prevailing performance against the performance from 2010 to 2025 to make sure the company is sustainable down the road. The current year's Market Cap is expected to grow to about 240.6 M, whereas Enterprise Value is forecasted to decline to about 95 M.

Cue Biopharma Total Revenue

3.6 Million

Check Cue Biopharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Cue Biopharma's main balance sheet or income statement drivers, such as Depreciation And Amortization of 4.1 M, Interest Expense of 1.2 M or Selling General Administrative of 11.7 M, as well as many indicators such as Price To Sales Ratio of 24.04, Dividend Yield of 0.0 or PTB Ratio of 3.56. Cue financial statements analysis is a perfect complement when working with Cue Biopharma Valuation or Volatility modules.
  
Check out the analysis of Cue Biopharma Correlation against competitors.
For information on how to trade Cue Stock refer to our How to Trade Cue Stock guide.

Cue Biopharma Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets66.4 M70.8 M44.8 M
Slightly volatile
Total Current Liabilities10.1 M19.6 M7.1 M
Slightly volatile
Total Stockholder Equity51.3 M42.6 M34.3 M
Slightly volatile
Other Liabilities2.5 M2.2 M1.7 M
Slightly volatile
Net Tangible Assets52.6 M75.5 M38.2 M
Slightly volatile
Property Plant And Equipment Net6.4 M8.2 M4.4 M
Slightly volatile
Accounts Payable4.2 M4 M1.5 M
Slightly volatile
Cash47.6 M55.8 M32.8 M
Slightly volatile
Non Current Assets Total8.6 M11.6 M5.9 M
Slightly volatile
Non Currrent Assets Other2.1 M3.2 M1.5 M
Slightly volatile
Other Assets2.1 M3.9 M1.6 M
Slightly volatile
Cash And Short Term Investments54.1 M55.8 M36.5 M
Slightly volatile
Common Stock Total Equity26.3 K49.5 K21.7 K
Slightly volatile
Common Stock Shares Outstanding30 M52.6 M27 M
Slightly volatile
Liabilities And Stockholders Equity66.4 M70.8 M44.8 M
Slightly volatile
Other Current Assets1.2 M1.4 M811 K
Slightly volatile
Other Stockholder Equity408.4 M389 M149.3 M
Slightly volatile
Total Liabilities15.1 M28.1 M10.6 M
Slightly volatile
Deferred Long Term Liabilities196.6 K299.3 K175.4 K
Slightly volatile
Property Plant And Equipment Gross7.7 M12.3 M5.4 M
Slightly volatile
Total Current Assets57.8 M59.2 M38.9 M
Slightly volatile
Common Stock29.1 K54 K22.4 K
Slightly volatile
Property Plant Equipment2.6 M1.7 M1.8 M
Slightly volatile
Short and Long Term Debt Total10.9 M16.9 M6.9 M
Slightly volatile
Current Deferred Revenue3 M2.4 M1.8 M
Slightly volatile
Net Receivables1.5 M2 M1.1 M
Slightly volatile
Inventory0.860.92 M
Very volatile
Net Invested Capital65.7 M52 M61.5 M
Pretty Stable
Short and Long Term Debt3.1 M4.6 M2.6 M
Slightly volatile
Net Working Capital42.3 M30.9 M53.9 M
Slightly volatile
Short Term Debt7.1 M8.4 M4.8 M
Slightly volatile
Intangible Assets10 K10.5 K93.2 K
Slightly volatile
Capital Surpluse237.6 M363.6 M177.7 M
Slightly volatile
Capital Stock36.6 K54 K28.5 K
Slightly volatile
Capital Lease Obligations8.5 M7.5 M6.7 M
Slightly volatile
Long Term Debt4.9 M3.8 M7.3 M
Slightly volatile
Long Term Debt Total6.4 M7.2 M7.9 M
Slightly volatile

Cue Biopharma Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Selling General Administrative11.7 M19.2 M8 M
Slightly volatile
Other Operating Expenses40.6 M66.3 M28 M
Slightly volatile
Research Development28.9 M46.9 M20 M
Slightly volatile
Total Operating Expenses35.9 M22.5 M22.6 M
Slightly volatile
Net Interest Income1.7 M1.6 M392.1 K
Slightly volatile
Interest Income3.2 M3.1 M698 K
Slightly volatile
Non Operating Income Net Other91.8 K57.7 K122.4 K
Slightly volatile
Selling And Marketing Expenses2.3 M2.6 M2.9 M
Slightly volatile

Cue Biopharma Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Cash From Financing Activities13 M13.6 M22.2 M
Slightly volatile
End Period Cash Flow47.7 M56 M32.9 M
Slightly volatile
Change To Netincome7.4 M10.9 M5.1 M
Slightly volatile
Stock Based Compensation7.8 M9.4 M5 M
Slightly volatile
Begin Period Cash Flow47 M59.5 M30.4 M
Slightly volatile
Issuance Of Capital Stock24 M12 M15.6 M
Slightly volatile
Net Borrowings12.3 M16.7 M11.1 M
Slightly volatile
Dividends Paid159.9 K179.9 K196.1 K
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio24.0425.371.0601
Slightly volatile
PTB Ratio3.563.7516.1602
Slightly volatile
Days Sales Outstanding99.0313087.2579
Pretty Stable
Book Value Per Share1.40.731.2205
Slightly volatile
Average Payables1.4 M2.4 M1.5 M
Slightly volatile
Stock Based Compensation To Revenue1.631.714.6838
Slightly volatile
PB Ratio3.563.7516.1602
Slightly volatile
EV To Sales17.3118.2255.6861
Slightly volatile
Inventory Turnover2.022.091.8689
Slightly volatile
Sales General And Administrative To Revenue6.493.497.7787
Slightly volatile
Average Inventory0.550.575.2 M
Slightly volatile
Research And Ddevelopement To Revenue15.538.5519.2924
Slightly volatile
Capex To Revenue0.150.160.9658
Slightly volatile
Cash Per Share1.510.951.3126
Slightly volatile
Income Quality0.610.710.7799
Slightly volatile
Intangibles To Total Assets2.0E-42.0E-40.0014
Slightly volatile
Net Debt To EBITDA1.680.842.0828
Slightly volatile
Current Ratio3.293.4611.2103
Slightly volatile
Tangible Book Value Per Share1.40.731.2199
Slightly volatile
Receivables Turnover2.762.915.215
Pretty Stable
Graham Number5.384.054.6354
Slightly volatile
Shareholders Equity Per Share1.40.731.2205
Slightly volatile
Debt To Equity0.370.360.1376
Slightly volatile
Capex Per Share0.00520.00550.0292
Slightly volatile
Graham Net Net0.470.50.9827
Slightly volatile
Average Receivables2.1 M1.8 M2.2 M
Slightly volatile
Revenue Per Share0.130.110.1031
Slightly volatile
Interest Debt Per Share0.250.310.221
Slightly volatile
Debt To Assets0.230.210.0965
Slightly volatile
Operating Cycle155130174
Slightly volatile
Price Book Value Ratio3.563.7516.1602
Slightly volatile
Ebt Per Ebit1.091.121.0088
Slightly volatile
Company Equity Multiplier1.021.491.2016
Slightly volatile
Long Term Debt To Capitalization0.110.120.8295
Slightly volatile
Total Debt To Capitalization0.270.260.1101
Slightly volatile
Debt Equity Ratio0.370.360.1376
Slightly volatile
Quick Ratio3.293.4611.1266
Slightly volatile
Net Income Per E B T1.111.151.0296
Slightly volatile
Cash Ratio3.13.2710.5385
Slightly volatile
Days Of Sales Outstanding99.0313087.2579
Pretty Stable
Free Cash Flow Operating Cash Flow Ratio1.21.151.2117
Slightly volatile
Price To Book Ratio3.563.7516.1602
Slightly volatile
Fixed Asset Turnover0.450.690.4884
Slightly volatile
Debt Ratio0.230.210.0965
Slightly volatile
Price Sales Ratio24.0425.371.0601
Slightly volatile
Asset Turnover0.05160.08030.045
Slightly volatile
Price Fair Value3.563.7516.1602
Slightly volatile

Cue Biopharma Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap240.6 M138.9 M230.5 M
Pretty Stable
Enterprise Value95 M100 M194.6 M
Slightly volatile

Cue Fundamental Market Drivers

Cash And Short Term Investments48.5 M

Cue Upcoming Events

19th of March 2024
Upcoming Quarterly Report
View
14th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
19th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Cue Biopharma Financial Statements

Cue Biopharma stakeholders use historical fundamental indicators, such as Cue Biopharma's revenue or net income, to determine how well the company is positioned to perform in the future. Although Cue Biopharma investors may analyze each financial statement separately, they are all interrelated. For example, changes in Cue Biopharma's assets and liabilities are reflected in the revenues and expenses on Cue Biopharma's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Cue Biopharma. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue2.4 M3 M
Total Revenue6.3 M3.6 M
Cost Of Revenue43.8 M46 M
Stock Based Compensation To Revenue 1.71  1.63 
Sales General And Administrative To Revenue 3.49  6.49 
Research And Ddevelopement To Revenue 8.55  15.53 
Capex To Revenue 0.16  0.15 
Revenue Per Share 0.11  0.13 
Ebit Per Revenue(8.55)(8.98)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
CRMSalesforce
CCitigroup
GMGeneral Motors
When determining whether Cue Biopharma is a strong investment it is important to analyze Cue Biopharma's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Cue Biopharma's future performance. For an informed investment choice regarding Cue Stock, refer to the following important reports:
How To Invest In Cue
Details
Is Cue Stock a good investment?
Details
What is Cue Biopharma's Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of Cue Biopharma Correlation against competitors.
For information on how to trade Cue Stock refer to our How to Trade Cue Stock guide.
You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cue Biopharma. If investors know Cue will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cue Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.91)
Revenue Per Share
0.192
Quarterly Revenue Growth
0.589
Return On Assets
(0.50)
Return On Equity
(1.31)
The market value of Cue Biopharma is measured differently than its book value, which is the value of Cue that is recorded on the company's balance sheet. Investors also form their own opinion of Cue Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Cue Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cue Biopharma's market value can be influenced by many factors that don't directly affect Cue Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
Please note, there is a significant difference between Cue Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cue Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cue Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY